- Home
- CRIS vs IRD Comparison
CRIS vs IRD Comparison
Compare CRIS & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- IRD
- Stock Information
- Founded
- CRIS 2000
- IRD 2018
- Country
- CRIS United States
- IRD United States
- Employees
- CRIS N/A
- IRD N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- IRD
- Sector
- CRIS Health Care
- IRD
- Exchange
- CRIS Nasdaq
- IRD NYSE
- Market Cap
- CRIS 21.3M
- IRD 62.0M
- IPO Year
- CRIS 2000
- IRD N/A
- Fundamental
- Price
- CRIS $1.75
- IRD $0.99
- Analyst Decision
- CRIS Strong Buy
- IRD Strong Buy
- Analyst Count
- CRIS 2
- IRD 3
- Target Price
- CRIS $16.50
- IRD $6.33
- AVG Volume (30 Days)
- CRIS 128.9K
- IRD 831.3K
- Earning Date
- CRIS 07-31-2025
- IRD 08-15-2025
- Dividend Yield
- CRIS N/A
- IRD N/A
- EPS Growth
- CRIS N/A
- IRD N/A
- EPS
- CRIS N/A
- IRD N/A
- Revenue
- CRIS $11,202,000.00
- IRD $13,651,000.00
- Revenue This Year
- CRIS N/A
- IRD $51.41
- Revenue Next Year
- CRIS $10.67
- IRD $68.84
- P/E Ratio
- CRIS N/A
- IRD N/A
- Revenue Growth
- CRIS 14.17
- IRD N/A
- 52 Week Low
- CRIS $1.02
- IRD $0.65
- 52 Week High
- CRIS $8.29
- IRD $2.18
- Technical
- Relative Strength Index (RSI)
- CRIS 34.36
- IRD N/A
- Support Level
- CRIS $2.11
- IRD N/A
- Resistance Level
- CRIS $2.48
- IRD N/A
- Average True Range (ATR)
- CRIS 0.21
- IRD 0.00
- MACD
- CRIS -0.06
- IRD 0.00
- Stochastic Oscillator
- CRIS 17.36
- IRD 0.00
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.